AAM
ALXN

Aberdeen Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Aberdeen Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$5.81M Buy
47,713
+731
+2% +$85.1K 0.02% 441
2017
Q1 		$5.7M Buy
46,982
+7,897
+20% +$1.02M 0.02% 433
2016
Q4 		$4.78M Sell
39,085
-12,132
-24% -$1.48M 0.02% 448
2016
Q3 		$6.28M Sell
51,217
-279
-0.5% -$35.9K 0.02% 399
2016
Q2 		$6.01M Sell
51,496
-668
-1% -$94.8K 0.02% 392
2016
Q1 		$7.26M Sell
52,164
-9,676
-16% -$1.42M 0.03% 348
2015
Q4 		$10.3M Buy
61,840
+9,357
+18% +$1.63M 0.04% 288
2015
Q3 		$8.21M Buy
52,483
+1,053
+2% +$192K 0.03% 295
2015
Q2 		$9.3M Sell
51,430
-1,030
-2% -$178K 0.03% 272
2015
Q1 		$9.09M Sell
52,460
-12,298
-19% -$2.23M 0.02% 265
2014
Q4 		$12M Sell
64,758
-80,632
-55% -$14.9M 0.03% 245
2014
Q3 		$24.1M Buy
145,390
+72,318
+99% +$11.9M 0.05% 188
2014
Q2 		$11.4M Buy
73,072
+51,772
+243% +$8.17M 0.02% 305
2014
Q1 		$3.24M Hold
21,300
– – 0.01% 253
2013
Q4 		$2.81M Hold
21,300
– – 0.01% 258
2013
Q3 		$2.47M Sell
21,300
-300
-1% -$32.9K 0.01% 263
2013
Q2 		$1.99M Buy
+21,600
New +$2.08M 0.01% 298

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Aberdeen Asset Management's ALXN Position: Q2 2017 in Review

Aberdeen Asset Management increased its Alexion Pharmaceuticals (ALXN) stake by 1.6% in Q2 2017, buying an estimated $85.1K and bringing the position to 47,713 shares worth $5.81M. The position accounts for 0.02% of the portfolio, ranked #441.

Aberdeen Asset Management first reported a position in ALXN in Q2 2013 and has held it in 17 quarters since. The position peaked at $24.1M in Q3 2014. 559 funds tracked by Wall St. Rank hold ALXN as of Q2 2017.

  • Aberdeen Asset Management held 47,713 shares of Alexion Pharmaceuticals worth $5.81M as of Q2 2017.
  • Aberdeen Asset Management bought 731 Alexion Pharmaceuticals shares in Q2 2017, an estimated $85.1K.
  • Alexion Pharmaceuticals made up 0.02% of Aberdeen Asset Management's portfolio in Q2 2017, its #441 holding.
  • Aberdeen Asset Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and has held it in 17 quarters since.
  • Aberdeen Asset Management's Alexion Pharmaceuticals position peaked at $24.1M in Q3 2014.
  • 559 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2017.

Based on Aberdeen Asset Management's 13F filing for Q2 2017, filed 10 Aug 2017.